Drug intelligence / Profile preview

IVX-003

Development stage: Preclinical
Lead developer: iProgen Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

IVX-003 is a preclinical-stage vaccine candidate being developed by iProgen Biotech in collaboration with academic partners. The agent is a protein conjugate, utilizing iProgen's proprietary delivery technology to enhance the immunogenicity and targeted delivery of vaccine antigens. While the specific pathogen or disease target for IVX-003 has not been publicly disclosed, it is part of iProgen's Immuno-Vaccine (IVX) platform, which focuses on creating next-generation vaccines through advanced protein engineering and conjugation techniques.

Beyond the preview

Go deeper on IVX-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVX-003.

Explore the full profile